Brain Metastases: From Mechanisms to Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 323
Special Issue Editors
Interests: drug delivery system to facilitate brain cancer-targeted molecular imaging diagnosis and imaging-guided drug delivery; novel nanoparticle-immunotherapy system to elicit anticancer immunity
Special Issue Information
Dear Colleagues,
Brain metastasis is the most common intracranial malignancy in adults. The current standard of care for brain metastasis includes surgical resection, stereotactic radiosurgery (SRS) and/or whole brain radiotherapy (WBRT). However, the prognosis for patients with brain metastasis is extremely poor, with a median survival of 8 to 16 months.
We are putting together a Special Issue of Cancers focusing on brain metastasis, which we hope will include recent advances in understanding mechanisms that underlie the development of brain metastasis and its tumor microenvironment (TME), such as the blood–tumor barrier (BTB), and in seeking new disease-specific biomarkers and novel treatment and combinatory treatment. We welcome contributions of both preclinical and clinical studies, as review articles or original research papers, on this clinically significant topic.
Prof. Dr. Dawen Zhao
Prof. Dr. Michael Chan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- brain metastasis
- the tumor microenvironment
- blood–tumor barrier
- novel biomarkers and therapeutics
- radiation therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
